First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.
IPO Year: 2021
Exchange: NYSE
Website: firstlightacquisition.com
| Date | Price Target | Rating | Analyst |
|---|
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
S-1/A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
EFFECT - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
S-1/A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
Fastest customizable press release news feed in the world
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP and intends to enter into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $50 million; proceeds to extend Calidi's cash runway
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that it convened and then adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 24, 2023 at 10:30 a.m., Eastern time (the "Special Meeting"). The adjourned Special Meeting will be held via the same live webcast at https://www.cstproxy.com/firstlightacquisition/2023. The Special Meeting is being held to consider and vote on, among other things, the business combination transaction between FLAG and Calidi Biotherapeutics, Inc. ("Calidi"), pursuant to an Agreement and Plan of Merger, dated January 9, 203, as amended, by and amo
RESTON, Va, Aug. 16, 2023 (GLOBE NEWSWIRE) -- irst Light Acquisition Group, Inc. ("FLAG") (NYSE:FLAG), a special purpose acquisition company, reminds FLAG stockholders that the FLAG Board of Directors unanimously recommends that FLAG stockholders vote FOR the proposed business combination (the "Business Combination") with Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses. The special meeting to consider and vote on the Business Combination will be held at 10:30 a.m. Eastern Time on August 22, 2023 via live webcast, as described in FLAG's proxy statement/prospectus dated
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. ("FLAG") (NYSE:FLAG), a special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective FLAG's registration statement on Form S-4 (as amended to the date hereof, the "Registration Statement"). The Registration Statement includes a proxy statement/prospectus for the special meeting of the stockholders of FLAG in connection with its proposed combination with Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses. FLAG has
SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group ("JIG"), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi. FLAG's
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and up to $42 million held in First Light trust account -Cash resources will fund Calidi's NeuroNova (CLD-101) and SuperNova (CLD-201) development programs into the 1st half of 2025 through multiple clinical milestones -Calidi's novel platform addresses a critical obstacle in traditional oncolytic virotherapy, overcoming virus inactivation through allogeneic stem cell delivery mechanism to [successfully] target a wide range of cancers, including high-grade gliomas and solid tumors -Business comb
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that its Board of Directors approved an extension of the date by which it has to consummate a business combination, allowing the Company to extend such date to March 14, 2023. This is consistent with the provisions approved by FLAG shareholders and published in the September 14, 2022 filing, which allow for the ability to extend for up to three additional times for three months each time, subject to the payment by FLAG's sponsor of 1% of the amount on deposit in FLAG's trust account for each extension (unless FLAG has filed a registration statement or proxy statement in conn
NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- CORRECTED version from November 14, 2022 5:00 a.m. release. First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG"), a special purpose acquisition company, announced today that it will transfer its listing to the NYSE American LLC ("NYSE American"), where it has been approved to list. In connection with the transfer, FLAG will voluntarily delist from The New York Stock Exchange. FLAG's decision to transfer to the NYSE American was motivated by more favorable thresholds for continued listing on the NYSE American following recent redemptions of FLAG's Class A common stock. Following the transfer, FLAG intends to continue to file the same types of
NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG"), a special purpose acquisition company, announced today that it will transfer its listing to the NYSE American LLC ("NYSE American"), where it has been approved to list. In connection with the transfer, FLAG will voluntarily delist from The New York Stock Exchange. FLAG's decision to transfer to the NYSE American was motivated by more favorable thresholds for continued listing on the NYSE American following recent redemptions of FLAG's Class A common stock. Following the transfer, FLAG intends to continue to file the same types of periodic reports and other information it currently files wi
This live feed shows all institutional transactions in real time.
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13D/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13D - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13D - Calidi Biotherapeutics, Inc. (0001855485) (Subject)